Mark W. Parrish, a director at Omnicell , Inc. (NASDAQ:OMCL), recently sold 12,000 shares of the company's common stock, according to a regulatory filing. The $2.13 billion market cap company has seen its stock surge over 61% in the past six months, though InvestingPro data shows it's currently not profitable. The shares were sold on December 10, 2024, at a weighted average price of $47.3032, resulting in a total transaction value of approximately $567,638. The sale price ranged between $46.98 and $47.64 per share. Following this transaction, Parrish holds 58,427 shares in the company. Analyst price targets for Omnicell range from $44 to $69, with expectations of profitability this year. For deeper insights into insider transactions and comprehensive analysis, access the full Pro Research Report on InvestingPro.
In other recent news, Omnicell, a medication management solutions provider, reported mixed Q3 results with a total revenue of $282 million, showing a sequential increase from the previous quarter but a decline from the same period last year. The company also announced its plans to offer $150 million of Convertible Senior Notes due 2029 and repurchase up to $400 million of its outstanding 0.25% Convertible Senior Notes due 2025. In terms of analyst updates, JPMorgan raised Omnicell's price target to $44 while maintaining a neutral stance, and BofA Securities adjusted its stance on Omnicell, reducing the price target to $54 from the previous $57 while also maintaining a neutral rating. The company's full-year 2024 guidance anticipates bookings between $800 million and $875 million, with total revenues expected to be between $1.1 billion and $1.110 billion. Non-GAAP EBITDA is projected to be between $129 million and $134 million, with non-GAAP earnings per share estimated to be $1.65 to $1.72. These recent developments reflect the evolving market environment and the company's strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.